SUMMARY  

• The safety and efficacy of ERLEADA for the treatment of breast cancer has not been established. Clinical judgement should be exercised when considering any use of ERLEADA outside of that listed in the approved labeling. Johnson & Johnson cannot recommend any practices, procedures, or dosing modifications that deviate from product labeling and are not approved by regulatory agencies.
• No prospective studies evaluating the use of ERLEADA for the treatment of breast cancer have been published.

LITERATURE SEARCH

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File (and/or other resources, including internal/external databases) conducted on 06 February 2025 did not identify any relevant citations pertaining to this topic.